Evidence map›Paper›PMID 39479486›Full record

ArticleRSC advances2024

Discovery of pyrazole-based analogs as CDK2 inhibitors with apoptotic-inducing activity: design, synthesis and molecular dynamics study.

Ghada M E Ali, Menna A Ewida, Amira M Elmetwali, Heba A Ewida, Riham F George, Walaa R Mahmoud, Nasser S M Ismail, Mahmoud S Ahmed, Hanan H Georgey

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ghada M E AliCentral Administration of Drug Control, EDA P.O. Box: 29 Cairo Egypt.
Menna A EwidaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Future University in Egypt Cairo 11835 Egypt Nasser.saad@fue.edu.eg.
Amira M ElmetwaliCentral Administration of Drug Control, EDA P.O. Box: 29 Cairo Egypt.
Heba A EwidaDepartment of Pharmacology and Biochemistry, Faculty of Pharmacy, Future University in Egypt Cairo 11835 Egypt.
Riham F GeorgePharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University Cairo 11562 Egypt.ORCID https://orcid.org/0000-0002-2493-1315
Walaa R MahmoudPharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University Cairo 11562 Egypt.
Nasser S M IsmailPharmaceutical Chemistry Department, Faculty of Pharmacy, Ain-Shams University Cairo 11566 Egypt.ORCID https://orcid.org/0000-0002-5119-9318
Mahmoud S AhmedPharmaceutical Sciences Department, School of Pharmacy, Texas Tech University Health Science Center Amarillo Texas USA mahmoudsalama.ahmed@ttuhsc.edu.
Hanan H GeorgeyPharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University Cairo 11562 Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The discovery of novel CDK2 inhibitors is crucial for developing targeted anticancer therapies. Thus, in this study, we aimed to design, synthesize, and evaluate a series of novel pyrazole derivatives (2a-g, 7a-d, 8a and b, 9, and 10) for their potential as CDK2/cyclin A2 enzyme inhibitors. The newly synthesized compounds were screened

Identifiers

PMID39479486
PMCPMC11520566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.